Update on the existing pre-clinical research collaboration agreement with a top-10 large pharma company

Posted on Dec 13, 2016

Oslo, December 13, 2016 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, reported today that the undisclosed top-10 pharma company has notified PCI Biotech that they intend to extend the existing research collaboration agreement, originally signed in September 2015, until the end of 2Q 2017. The aim of the extension is to further […]

PCI Biotech and eTheRNA immunotherapies initiate research collaboration

Posted on Dec 8, 2016

Oslo (Norway) and Niel (Belgium), 8 December 2016 — PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and eTheRNA immunotherapies NV, a VUB spin-off company backed by strong life science investors to continue the development of mRNA-based immunotherapies, today announced that they are initiating a preclinical research collaboration. The partnership is governed by a preclinical […]

Rights issue approved by the extraordinary general meeting

Posted on Dec 8, 2016

Oslo, 8 December, 2016. An extraordinary general meeting (the “EGM”) of the shareholders of PCI Biotech Holding ASA (“PCI Biotech”) was held today, 8 December 2016 at 09:00 CET. 8,527,123 shares were represented at the meeting, corresponding to 57.2 percent of the share capital. The EGM approved the Board of Directors’ proposed resolutions as set […]